Quarterly report pursuant to Section 13 or 15(d)

Revenue - Additional Information (Detail)

v3.22.1
Revenue - Additional Information (Detail) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation Of Revenue [Line Items]    
Revenue $ 687,000 $ 12,050,000
Income tax expense (4,700,000) 1,100,000
Exclusive License And Collaboration Agreement    
Disaggregation Of Revenue [Line Items]    
Non refundable upfront payment received 10,000,000.0  
Transaction price 12,100,000  
Fixed upfront cash payment 10,000,000.0 10,000,000.0
Amount related to withholding tax obligations 1,100,000  
Revenue recognized 0 1,100,000
Income tax expense   1,100,000
Exclusive License And Collaboration Agreement | Maximum    
Disaggregation Of Revenue [Line Items]    
Potential development and commercial milestones yet to receive 110,000,000.0  
Asset Purchase Agreement | Cypralis Limited    
Disaggregation Of Revenue [Line Items]    
Revenue recognized 0 0
License Agreement | Waterstone Pharmaceutical HK Limited    
Disaggregation Of Revenue [Line Items]    
Revenue recognized $ 0 0
Sales Revenue Net | Customer Concentration Risk | Wholesaler One    
Disaggregation Of Revenue [Line Items]    
Percentage of gross revenue 46.00%  
Sales Revenue Net | Customer Concentration Risk | Wholesaler Two    
Disaggregation Of Revenue [Line Items]    
Percentage of gross revenue 29.00%  
Sales Revenue Net | Customer Concentration Risk | Wholesaler Three    
Disaggregation Of Revenue [Line Items]    
Percentage of gross revenue 21.00%  
Product Revenue, Net    
Disaggregation Of Revenue [Line Items]    
Revenue $ 687,000 $ 0